Development of an Optimized Adjuvanted TB Vaccine

NIH Pandemic-Era Grants

Pandemic Era Grants

2022

↗ Live URL (may be dead)

Document text

Principal Investigator: JAY  EVANS
Organization: UNIVERSITY OF MONTANA
Fiscal Year: 2022
Award: $2,076,197
Funding agency: National Institute of Allergy and Infectious Diseases

Vaccine Adjuvant Discovery Program: To develop a lead, optimized adjuvanted tuberculosis (TB) vaccine for IM or IN administration using specified adjuvants in combination with recombinant or circRNA TB antigens within the context
of a vaccine to prevent TB.

Terms: <Adjuvant><Antigens><Development><M tuberculosis infection><M. tb infection><M. tuberculosis infection><M.tb infection><M.tuberculosis infection><MTB infection><MTB vaccine><Messenger RNA><Mice><Mice Mammals><Modeling><Murine><Mus><Mycobacterium tuberculosis (MTB) infection><Mycobacterium tuberculosis infection><Recombinant Proteins><Recombinants><Specific qualifier value><Specified><TB infection><TB vaccine><Tuberculosis><Tuberculosis Vaccines><Vaccine Adjuvant><Vaccine for TB><Vaccine for Tuberculosis><Vaccines><anti-TB vaccine><developmental><disseminated TB><disseminated tuberculosis><efficacy testing><immunogen><infection due to Mycobacterium tuberculosis><lead optimization><mRNA><prevent><preventing><programs><tuberculosis infection><tuberculous spondyloarthropathy>